# SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05631262/  
OnCo record `nct05631262` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Docetaxel in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors is a phase 2 interventional study registered as NCT05631262 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 321 participants enrolled, started 2022-11-30 and due to reach its primary completion in 2026-12-30. Interventions recorded: SKB264 and Docetaxel.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05631262
- Phase: 2
- Setting: A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 321

## Sources

- ClinicalTrials.gov NCT05631262: https://clinicaltrials.gov/study/NCT05631262

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05631262.json